1. New cyclic arylguanidine scaffolds as a platform for development of antimicrobial and antiviral agents.
- Author
-
Zaręba P, Drabczyk AK, Wnorowska S, Wnorowski A, and Jaśkowska J
- Subjects
- Antiviral Agents pharmacology, Microbial Sensitivity Tests, SARS-CoV-2, Staphylococcus aureus, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents chemistry, Antifungal Agents pharmacology, COVID-19, Anti-Infective Agents pharmacology, Cryptococcus neoformans
- Abstract
According to WHO, infectious diseases are still a significant threat to public health. The combine effects of antibiotic resistance, immunopressure, and mutations within the bacterial and viral genomes necessitates the search for new molecules exhibiting antimicrobial and antiviral activities. Such molecules often contain cyclic guanidine moiety. As part of this work, we investigated the selected antimicrobial and antiviral activity of compounds from the cyclic arylguanidine group. Molecules were designed using molecular modeling and obtained using microwave radiation (MW) and sonochemical ()))) methods, in accordance with the previously developed pathways. The obtained compounds were screened for the ability to inhibit the growth of Escherichia coli, Acinetobacter baumannii, Pseudomonas aeruginosa, Staphylococcus aureus, Candida albicans, and Cryptococcus neoformans. The capacity to block the entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into the host cell was probed using a bioluminescence immunoassay. The cytotoxicity and hemolytic properties of the most active molecules were also evaluated. The N-[2-(naphthalen-1-yl)ethyl]-5-phenyl-1,4,5,6-tetrahydro-1,3,5-triazin-2-amine 12j showed a high inhibition of Staphylococcus aureus and Cryptococcus neoformans (MIC ≤ 0.25 µg/mL), with no cytotoxic nor hemolytic effect (CC
50 , HC10 > 32 µm/mL). The CO-ADD platform identified many potentially useful molecules. A particularly rich population was examined in the database of the N.D. Zelinsky Institute of Organic Chemistry, in which 2517 active molecules (MIC ≤ 32 mg/mL) were found, of which about 10% are active at very low concentrations (MIC ≤ 1 mg/mL)., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Przemyslaw Zareba reports financial support was provided by Cracow University of Technology Faculty of Chemical Engineering and Technology. Przemyslaw Zareba reports equipment, drugs, or supplies was provided by AGH University of Science and Technology Academic Computer Centre Cyfronet. Przemyslaw Zareba reports equipment, drugs, or supplies was provided by University of Queensland. Sylwia Wnorowska reports financial support was provided by Medical University of Lublin., (Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.)- Published
- 2023
- Full Text
- View/download PDF